Author details

Full Name

John Connelly

Affiliation

Institute of Genetics and Cancer, University of Edinburgh

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36351380	Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer.	Cell Rep	2022
36351380	Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer.	Cell Rep	2022
34676045	ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomide.	Oncotarget	2021
34676045	ATR inhibition reverses the resistance of homologous recombination deficient MGMT<sup>low</sup>/MMR<sup>proficient</sup> cancer cells to temozolomide.	Oncotarget	2021
32586373	Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.	Clin Epigenetics	2020
32586373	Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.	Clin Epigenetics	2020
31102023	Exposure time versus cytotoxicity for anticancer agents.	Cancer Chemother Pharmacol	2019
31102023	Exposure time versus cytotoxicity for anticancer agents.	Cancer Chemother Pharmacol	2019
29196464	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.	Cancer Discov	2018
30355619	The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.	Cancer Res	2018
29196464	Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.	Cancer Discov	2018
30355619	The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.	Cancer Res	2018
27247353	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.	J Natl Cancer Inst	2016
27247353	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.	J Natl Cancer Inst	2016
27265504	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.	Cancer Cell	2016
27265504	CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.	Cancer Cell	2016
26351324	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.	Mol Cancer Ther	2015
26351324	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.	Mol Cancer Ther	2015
21765476	CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.	Oncogene	2012
21765476	CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.	Oncogene	2012
19741151	Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].	J Pharmacol Exp Ther	2009
19741151	Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].	J Pharmacol Exp Ther	2009
16332985	Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.	Mol Pharmacol	2006
16332985	Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.	Mol Pharmacol	2006
12606787	Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.	Mol Pharmacol	2003
12606787	Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.	Mol Pharmacol	2003
10857990	UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.	Invest New Drugs	2000
10857990	UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.	Invest New Drugs	2000

1 - 28 of 28

Andrew Goodspeed

University of Colorado Denver | Anschutz Medical Campus

Career Start Year 2013

Number of shared co-authors 0

Aleksandra M Michalowski

Center for Cancer Research, National Cancer Institute

Career Start Year 2010

Number of shared co-authors 4

Yisong Wang

Lombardi Comprehensive Cancer Center, Georgetown University

Career Start Year 2010

Number of shared co-authors 2

Frederick S Vizeacoumar

College of Medicine, University of Saskatchewan

Career Start Year 2010

Number of shared co-authors 0

Jordi Carreras Puigvert

Department of Pharmaceutical Biosciences, Uppsala University

Career Start Year 2009

Number of shared co-authors 0

Kris C Wood

Duke University

Career Start Year 2005

Number of shared co-authors 0

Aik Choon Tan

Huntsman Cancer Institute, The University of Utah

Career Start Year 2003

Number of shared co-authors 0

Xiaohu Zhang

National Center for Advancing Translational Sciences

Career Start Year 2003

Number of shared co-authors 4

Justin Cidado

Oncology R&D

Career Start Year 2003

Number of shared co-authors 0

Elena Ivanova

Dana-Farber Cancer Institute

Career Start Year 2003

Number of shared co-authors 0

Lixia Diao

The University of Texas MD Anderson Cancer Center

Career Start Year 2003

Number of shared co-authors 0

Eddy S Yang

University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center

Career Start Year 1999

Number of shared co-authors 0

Mathew J Garnett

Wellcome Sanger Institute

Career Start Year 1998

Number of shared co-authors 3

Peter S Hammerman

Novartis Institutes for BioMedical Research

Career Start Year 1996

Number of shared co-authors 1

Kimberly Stegmaier

Dana-Farber Cancer Institute

Career Start Year 1995

Number of shared co-authors 1

Krister Wennerberg

University of Copenhagen

Career Start Year 1994

Number of shared co-authors 0

Timothy A Chan

Cleveland Clinic.

Career Start Year 1994

Number of shared co-authors 0

Michael Peyton

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center

Career Start Year 1994

Number of shared co-authors 0

Ultan McDermott

Wellcome Sanger Institute

Career Start Year 1993

Number of shared co-authors 0

Ricky W Johnstone

The University of Melbourne

Career Start Year 1990

Number of shared co-authors 1

Todd R Golub

Broad Institute of MIT and Harvard

Career Start Year 1989

Number of shared co-authors 2

Charles M Rudin

Memorial Sloan Kettering Cancer Center

Career Start Year 1989

Number of shared co-authors 1

David S Schrump

Center for Cancer Research, National Cancer Institute

Career Start Year 1988

Number of shared co-authors 5

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 0

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 1

Charles L Sawyers

Memorial Sloan Kettering Cancer Center

Career Start Year 1986

Number of shared co-authors 0

Scott H Kaufmann

Mayo Clinic

Career Start Year 1977

Number of shared co-authors 3

Paul Workman

The Institute of Cancer Research

Career Start Year 1974

Number of shared co-authors 0

Antonio Jimeno

University of Colorado School of Medicine

Career Start Year 1974

Number of shared co-authors 0

Dennis J Slamon

David Geffen School of Medicine at university of california los angeles

Career Start Year 1973

Number of shared co-authors 1

row(s) 1 - 30 of 30

Anne Monks

Institute of Biomedical Engineering (IBME), University of Oxford

Co-authored papers 9

James H Doroshow

National Cancer Institute, National Institutes of Health

Co-authored papers 4

Eric C Polley

Mayo Clinic

Co-authored papers 3

Dmitriy Sonkin

National Cancer Institute

Co-authored papers 3

Yves Pommier

Center for Cancer Research, National Cancer Institute

Co-authored papers 3

Gabriele Zoppoli

University of Genoa and Ospedale Policlinico San Martino

Co-authored papers 2

Paul S Meltzer

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Co-authored papers 2

Joel Morris

National Cancer Institute

Co-authored papers 2

William C Reinhold

Center for Cancer Research, National Cancer Institute

Co-authored papers 2

Robert H Shoemaker

National Cancer Institute

Co-authored papers 2

Ogan D Abaan

Illumina Inc.

Co-authored papers 1

Alison Meynert

Institute of Genetics and Cancer, University of Edinburgh

Co-authored papers 1

Richard Simon

National Cancer Institute

Co-authored papers 1

Natasha J Caplen

Co-authored papers 1

Benjamin G Vincent

UNC School of Medicine, The University of North Carolina at Chapel Hill

Co-authored papers 1

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Co-authored papers 1

St??phanie Solier

Gustave Roussy Cancer Center, INSERM U1170

Co-authored papers 1

Jonathan S Serody

The University of North Carolina School of Medicine

Co-authored papers 1

Susan R Davis

Co-authored papers 1

Graeme R Grimes

Co-authored papers 1

James D Brenton